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To the Editor,
Validation of results is one of the core tasks of laboratory 
medicine specialists. This work includes a technical com-
ponent, often achieved by maintaining internal and exter-
nal quality control (QC) within preset limits, but also has 
an important medical component. By reviewing results, a 
specialist can filter out unexpected or contradictory results 
and subject them to further examination. The specialist 
hereby has to integrate knowledge of pathophysiology 
with technical competence. This manual test validation 
has the disadvantage of being time-consuming with large 
inter-individual variation which subsequently slows down 
the response time of the laboratory to the clinic. Special-
ists try to cope with this problem by installing pre-defined 
triggers for absurd values (probably caused by a technical 
or sampling flaw, panic values, etc.) and by reviewing of a 
subset of ‘unexpected’ results, where unexpected is often 
defined as an abnormally high or low value or, most often, 
as a consecutive value trespassing the reference change 
value (RCV) based on within-subject biological variation 
and analytical CV (delta check). A possible solution can be 
found in commercial packages that are extensively used 
to filter out results for review [1, 2]. To efficiently use such 
models, there is a need for useful estimates of biological 
variation. For therapeutic drug monitoring (TDM) this has 
been historically a difficult issue. Recently, we published 
practice-oriented criteria for some drugs based on a proxy 
for biological variation of drugs in blood both within-and 
between-subject [3]. Here we present similar calculations 
for a large number of therapeutic drugs monitored in our 
lab. Further, we use the calculated within-subject varia-
tions in a delta check algorithm to filter out results which 
could merit closer inspection. We give proof-of-concept 
for vancomycin and tacrolimus, representing the two drug 
classes (i.e. antibiotics and immunosuppressants).
For five antibiotics and five immunosuppressants rou-
tinely monitored in our lab, we retrospectively checked 
our laboratory information system during a 1-year period 
(December 1st, 2012 to November 31st, 2013). We included 
consecutive drug level determinations for patients receiv-
ing the medication that were both within the proposed 
therapeutic range to exclude possible dosing changes, 
pre-analytical flaws or major patient instabilities. We 
further calculated the difference between the two consecu-
tive concentrations for each patient and drug. Outliers in 
these differences, unlikely to be caused only by biologi-
cal variation, were detected and excluded by means of a 
Tukey filter [4]. Determinations were made by the same 
method on the same instrument. Everolimus, sirolimus 
and mycophenolate are measured using liquid chroma-
tography mass spectrometry (LC-MS/MS) using an in-
house validated assay [5, 6]; tacrolimus and cyclosporine 
are measured using the Architect SR2000i immunoas-
say. Vancomycin, gentamycin, amikacin and tobramycin 
concentrations are determined on a Roche Cobas 8000 
(Roche Diagnostics, Mannheim, Germany). For voricona-
zole, a previously described LC-MS/MS assay is used [7]. 
Within- and between-patient variability was calculated 
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using the CLSI EP5A-02 standard protocols [8]. Further, the 
analytical variability (CVA), which was determined by the 
monthly instrument CV on the quality control level closest 
to the average of the respective consecutive measure-
ments, was subtracted from the raw within-subject (CVI,raw) 
or between-subject (CVG,raw) variation using the formula 
− =
2 2 2
I /G,raw A I/G(CV ) (CV ) (CV ). For both immunosuppressants 
and antibiotics, the results are presented in Table 1. We 
proposed quality specifications based on the feasibility 
index (TEa/CVA).
Further, we prospectively examined the differences 
between consecutive measurements for two patients 
receiving vancomycin and tacrolimus, respectively. 
To assess the significance of the differences of serial 
results, the 95% RCV was calculated using the formula: 
1/ 2 2 2 1/ 2
A I2 (CV CV ) ;z −  were z is the coverage factor (1.96) 
corresponding to the 95% confidence interval, CVA the 
analytical coefficient of variation and CVI the corrected 
within-subject variation [9]. For each sample, the request-
ing physician was contacted to ask the dose of the drug the 
patient received, the time at which the drug was adminis-
tered, and the time at which a sample for TDM was drawn. 
The results are presented in Figure 1.
Based on this RCV filter, we propose an algorithm to 
identify samples that merit closer inspection. We suggest 
that all first patient values outside the therapeutic inter-
val are reviewed by a laboratory medicine specialist 
giving a comment on how to change the dose and when 
to re-evaluate the effect. For values within the therapeu-
tic interval, no review is needed and the RCV can be used 
for serial results to check for major pre-analytical flaws, 
unnecessary dosing changes or unstable patient situa-
tions. For values outside the reference interval, the cal-
culated RCV on the serial result can be used to calculate 
whether the dosage change had an effect (if there was 
one). If the RCV is not surpassed or if the serial value does 
not enter the therapeutic interval, special attention from 
the laboratory medicine specialist can be of value. By this 
algorithm, only 30% and 22% of the samples of our van-
comycin and tacrolimus patient would need attention, 
respectively.
We aimed to determine the normal between-person 
variation in a steady-state therapeutic situation (as a proxy 
for healthy individuals in a biological variation study for 
endogenous analytes), after the therapeutic regimen has 
been optimized for the patients specific characteristics 
(e.g. genetics). Thus our study design does not cover the 
total between-patient variation of drug levels. We are 
aware that taking these factors into account the total vari-
ation would be higher. In fact, these factors are the reason 
for performing TDM of these drugs.
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We also noticed that for some drugs, the calculated 
within-subject variation was lower than the currently 
achieved analytical variation (e.g. cyclosporine, mycophe-
nolate) (Table 1). This implies that the lion’s share of 
variability between two consecutive results within the 
therapeutic range can be ascribed to analytical variation. 
The implication is that true but smaller changes in steady-
state concentrations will be swamped by analytical varia-
tions, but larger and clinically relevant sampling or dosing 
errors are picked up. We are aware that the calculated 
biological variations can still be contaminated with some 
pre- analytical variation. Also, deviations in dose or health 
from patients cannot be excluded. However, we introduced 
some precautions by using only consecutive levels within 
the therapeutic range and also an outlier filter for unusu-
ally large differences between consecutive measurements, 
indicating deviations or substantial pre-analytical flaws. 
Last, we provided proof-of-concept for the applicability 
of the calculated biological variation to filter out relevant 
results (dosing change, pre-analytical flaws) in our setting.
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Figure 1: Vancomycin concentration profile (A) and tacrolimus concentration profile (B) of two different patients.
The open dots present the concentrations that fall out of the 95% reference change value (RCV). For each profile, a reason for the differ-
ence is given. Panel A: 1. Concentration 7.0 mg/L: patient did not receive vancomycin; 2. 7.0 mg/L: patient did not receive vancomycin; 3. 
Concentration 21.3 mg/L: change in vancomycin dose; 4. Concentration: 9.0 mg/L: patient did not receive vancomycin; 5. Concentration: 
21.9 mg/L: restart of vancomycin dose; 6. Concentration 6.6 mg/L: wrong sampling time (20 h instead of 14 h); 7. Concentration: 12.7 mg/L: 
restart vancomycin dose. Panel B: 1. 13.5 μg/L: patient received a double dose (8 mg instead of 4 mg); 2. 6.5 μg/L: change in tacrolimus 
dose; 3. 4.0 μg/L: patient did not receive tacrolimus; 4. 6.5 μg/L: restart tacrolimus administration; 5.: 10.4 μg/L: patient received 7 mg 
instead of 4 mg; 6. 5.1 μg/L: patient did not receive tacrolimus.
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